A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance

作者: Shang-Hsun Tsou , Tzer-Ming Chen , Hui-Ting Hsiao , Yen-Hui Chen

DOI: 10.1371/JOURNAL.PONE.0116747

关键词:

摘要: Cellular mechanisms of multidrug resistance (MDR) are related to ABC transporters, apoptosis, antioxidation, drug metabolism, DNA repair and cell proliferation. It remains unclear whether the process development is programmable. We aimed study gene expression profiling circumstances in MCF-7 during MDR development. Eleven sublines with incremental doxorubicin were established as a valued tool progression. marker P-gp was overexpressed only cells termed MCF-7/ADR-1024 under selection dose approaching 1024 nM. authentic MCF-7/ADR shared common features morphology ploidy status. down regulated genes BRCA1/2 wild type p53, apoptosis-related Bcl-2 epithelial-mesenchymal transition (EMT) epithelial E-cadherin. While detoxifying enzymes glutathione-S transferase-π protein kinase C-α up-regulated. The involving EMT mesenchymal formation also overexpressed, including N-cadherin, vimentin E-cadherin transcription reppressors Slug, Twist ZEB1/2. PI3K/AKT inhibitor wortmannin suppressed mdr1. Mutant p53 deletion at codons 127-133 markedly appeared well. In addition, exerted CSC-like surface CD44 high/CD24 low form mammospheres. Overall, results suggest that arises owing turn on/off or mutation involved repair, enzymes, transporters turning point (1.024 μM challenge). Behind this point, no obvious alterations found most tested genes. Selection for may importantly attribute propagation population presenting invasive properties resistance. thereby two models induction Model 1: cells. 2: Mutations gain-of Either model 1 2 requires alter regulation.

参考文章(56)
Bora Lim, Leah V. Cream, Harold A. Harvey, Update on Clinical Trials: Genetic Targets in Breast Cancer Advances in Experimental Medicine and Biology. ,vol. 779, pp. 35- 54 ,(2013) , 10.1007/978-1-4614-6176-0_2
Robert O'connor, The pharmacology of cancer resistance. Anticancer Research. ,vol. 27, pp. 1267- 1272 ,(2007)
James J Ryan, Edward Prochownik, Christopher A Gottlieb, Ingrid J Apel, Ramon Merino, Gabriel Nunez, Michael F Clarke, c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 5878- 5882 ,(1994) , 10.1073/PNAS.91.13.5878
Kathleen W Scotto, Transcriptional regulation of ABC drug transporters Oncogene. ,vol. 22, pp. 7496- 7511 ,(2003) , 10.1038/SJ.ONC.1206950
Sung-Tsai Yu, Tzer-Ming Chen, Shih-Yun Tseng, Yen-Hui Chen, Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells Biochemical and Biophysical Research Communications. ,vol. 358, pp. 79- 84 ,(2007) , 10.1016/J.BBRC.2007.04.107
Steve A. Maxwell, Jack A. Roth, Posttranslational regulation of p53 tumor suppressor protein function Critical Reviews in Oncogenesis. ,vol. 5, pp. 23- 57 ,(1994) , 10.1615/CRITREVONCOG.V5.I1.20
Marcia Munoz, Michelle Henderson, Michelle Haber, Murray Norris, Role of the MRP1/ABCC1 multidrug transporter protein in cancer. Iubmb Life. ,vol. 59, pp. 752- 757 ,(2007) , 10.1080/15216540701736285
Anne-Pierre Morel, Marjory Lièvre, Clémence Thomas, George Hinkal, Stéphane Ansieau, Alain Puisieux, Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition PLoS ONE. ,vol. 3, pp. e2888- ,(2008) , 10.1371/JOURNAL.PONE.0002888